📊 MNKD Key Takeaways
Is Mannkind Corp. (MNKD) a Good Investment?
MannKind demonstrates revenue growth of 22.2% YoY and positive operating cash flow, indicating operational progress in a pharmaceutical environment. However, negative stockholders' equity of -51.0M, high debt burden of 354.6M, and deteriorating diluted EPS (-80% YoY) present substantial balance sheet concerns that offset near-term operational improvements.
Revenue growth is strong and operating profitability has turned positive, producing modest free cash flow and adequate liquidity. However, net margins remain thin, equity is negative, and leverage is meaningful, leaving limited cushion if growth or margins soften. Sustained cash generation and margin expansion are needed to repair the balance sheet and improve durability.
Why Buy Mannkind Corp. Stock? MNKD Key Strengths
- Strong revenue growth of 22.2% YoY signals market demand and commercial execution
- Positive operating cash flow of 18.3M and free cash flow of 13.7M demonstrate ability to generate cash from operations
- Adequate liquidity with current ratio of 1.70x and cash position of 74.9M provides short-term financial flexibility
- Operating margin of 11.1% shows reasonable cost control at the operational level
- 22.2% YoY revenue growth indicating solid demand momentum
- Positive operating income with 11.1% margin and positive FCF
- Adequate liquidity (current ratio 1.7x; quick ratio 1.5x)
MNKD Stock Risks: Mannkind Corp. Investment Risks
- Negative stockholders' equity of -51.0M indicates the company is technically insolvent on a balance sheet basis
- High long-term debt of 354.6M relative to operating cash flow creates refinancing and debt service risks
- Net margin of only 1.7% despite revenue growth shows minimal bottom-line profitability after interest and debt obligations
- Diluted EPS collapsed 80% YoY, signaling significant share dilution and deteriorating per-share economics
- Interest coverage of 4.5x provides limited cushion if operational performance declines
- Negative stockholders' equity and sizable long-term debt load
- Very thin net margin (1.7%) and sharply lower diluted EPS
- Interest coverage only moderate at 4.5x, sensitive to margin compression
Key Metrics to Watch
- Trajectory of net income and diluted EPS to assess if profitability gains are sustainable
- Debt reduction progress and debt-to-operating cash flow ratio as indicator of financial stability
- Path to positive stockholders' equity through retained earnings accumulation
- Operating cash flow sustainability and conversion efficiency from revenue to cash
- Net margin
- Operating cash flow
Mannkind Corp. (MNKD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 3.9% FCF margin may limit capital allocation flexibility.
MNKD Profit Margin, ROE & Profitability Analysis
MNKD vs Healthcare Sector: How Mannkind Corp. Compares
How Mannkind Corp. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Mannkind Corp. Stock Overvalued? MNKD Valuation Analysis 2026
Based on fundamental analysis, Mannkind Corp. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Mannkind Corp. Balance Sheet: MNKD Debt, Cash & Liquidity
MNKD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Mannkind Corp.'s revenue has grown significantly by 363% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.04 indicates the company is currently unprofitable.
MNKD Revenue Growth, EPS Growth & YoY Performance
MNKD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $70.1M | $668.0K | $0.03 |
| Q2 2025 | $72.4M | $668.0K | $0.00 |
| Q1 2025 | $66.3M | $10.6M | $0.04 |
| Q3 2024 | $51.3M | $1.7M | $0.01 |
| Q2 2024 | $48.6M | -$2.0M | $-0.01 |
| Q1 2024 | $40.6M | -$9.8M | $-0.04 |
| Q3 2023 | $32.8M | $1.7M | $0.01 |
| Q2 2023 | $18.9M | -$5.3M | $-0.02 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Mannkind Corp. Dividends, Buybacks & Capital Allocation
MNKD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Mannkind Corp. (CIK: 0000899460)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MNKD
What is the AI rating for MNKD?
Mannkind Corp. (MNKD) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 63% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MNKD's key strengths?
Claude: Strong revenue growth of 22.2% YoY signals market demand and commercial execution. Positive operating cash flow of 18.3M and free cash flow of 13.7M demonstrate ability to generate cash from operations. ChatGPT: 22.2% YoY revenue growth indicating solid demand momentum. Positive operating income with 11.1% margin and positive FCF.
What are the risks of investing in MNKD?
Claude: Negative stockholders' equity of -51.0M indicates the company is technically insolvent on a balance sheet basis. High long-term debt of 354.6M relative to operating cash flow creates refinancing and debt service risks. ChatGPT: Negative stockholders' equity and sizable long-term debt load. Very thin net margin (1.7%) and sharply lower diluted EPS.
What is MNKD's revenue and growth?
Mannkind Corp. reported revenue of $349.0M.
Does MNKD pay dividends?
Mannkind Corp. does not currently pay dividends.
Where can I find MNKD SEC filings?
Official SEC filings for Mannkind Corp. (CIK: 0000899460) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MNKD's EPS?
Mannkind Corp. has a diluted EPS of $0.02.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MNKD a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Mannkind Corp. has a HOLD rating with 63% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MNKD stock overvalued or undervalued?
Valuation metrics for MNKD: ROE of N/A (sector avg: 15%), net margin of 1.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MNKD stock in 2026?
Our dual AI analysis gives Mannkind Corp. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MNKD's free cash flow?
Mannkind Corp.'s operating cash flow is $18.3M, with capital expenditures of $4.6M. FCF margin is 3.9%.
How does MNKD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 1.7% (avg: 12%), ROE N/A (avg: 15%), current ratio 1.70 (avg: 2).